Key Highlights:
- Three share consolidations are slated for Monday, October 26, 2026, at Top Wealth Group, China SXT Pharmaceuticals and Solowin Holdings.
- MicroVision reports third-quarter results on October 28, five days after Friday's session (calculated).
- LKQ and Phathom Pharmaceuticals both report on October 29, 2026, six days out (calculated).
- Tango Therapeutics faces the ESMO Congress in Madrid, which runs through October 27, 2026.
- WiSeSat.Space has a satellite launch planned for October 2026 but no announced date.
Which Stocks Have Dated Catalysts in the Week of October 26, 2026?
Eight stocks that moved on Friday, October 23, 2026, have events ahead, and seven of them have a specific date. LKQ (NASDAQ:LKQ) fell 19.60% to $18.07 after preliminary results, and full third-quarter results follow October 29. MicroVision (NASDAQ:MVIS) rose 8.77% to $1.24 ahead of an October 28 report. Phathom Pharmaceuticals (NASDAQ:PHAT) fell 15.55% to $5.92 before its October 29 webcast. Tango Therapeutics (NASDAQ:TNGX) fell 15.11% to $23.71 as ESMO opened. Top Wealth Group (NASDAQ:TWG), China SXT Pharmaceuticals (NASDAQ:SXTC) and Solowin Holdings (NASDAQ:AXG) fell 15.68%, 10.63% and 21.85% before October 26 consolidations. WiSeSat.Space (NASDAQ:SAIQ) rose 30.83% to $6.91 with no dated event.
LKQ: What Will the October 29 Report Add to the Preliminary Numbers?
The auto parts distributor already issued preliminary third-quarter figures on October 23, showing revenue of $3.32 billion, down about 5.1% (calculated), and adjusted EPS of $0.47 to $0.53 against $0.84. It withdrew 2026 guidance and said its chief executive had left. The full report and call on October 29 are the first chance to hear detail on weak European volumes and an ERP disruption. A new chief executive starts December 15, 2026, which is 47 days after the report (calculated). Adjusted net income was guided at $119 million to $135 million against $216 million a year earlier.
MicroVision: Can Third-Quarter Revenue Bridge the Gap to Guidance?
The lidar developer reports on October 28, 2026. Its full-year revenue target of $10 million to $15 million, reaffirmed in May, compares with about $2.4 million in the first half (calculated), so the second half would need $7.6 million to $12.6 million (calculated). Cash and securities were $27.2 million on June 30, and management expects 2026 cash burn near $60 million. The company has not announced a catalyst for Friday's gain.
Phathom Pharmaceuticals: Is the Revenue Range Intact Going Into October 29?
The company will hold a third-quarter webcast on October 29 at 8:00 a.m. EDT. Second-quarter VOQUEZNA net revenue rose 88% to $74.3 million, and in July the company trimmed its 2026 revenue range to $310 million to $325 million. Cash was $182.5 million at June 30 against total liabilities of $671.3 million. No catalyst has been announced for the Friday decline, and a fourth-quarter topline readout in eosinophilic esophagitis is also expected.
Tango Therapeutics: Will ESMO Data Back the Earlier Response Rate?
The ESMO Congress runs October 23 to 27, 2026, and the company said in August it would present Phase 1/2 data for vopimetostat with RAS(ON) inhibitors there. An earlier cohort showed a 92% objective response rate and a 90% six-month progression-free survival rate in pancreatic cancer. Cash was $1.0 billion at June 30, and the second-quarter net loss was $55.3 million. Friday's close of $23.71 sits about 14.3% below the August 10 close of $27.67 (calculated). The company has not announced a catalyst for Friday's fall or a date for its third-quarter results.
Top Wealth Group: What Changes When the Share Consolidation Starts?
The caviar and wine seller, a Cayman Islands holding company with a Hong Kong subsidiary, says a 1-for-100 consolidation takes effect October 26, after a corrected date. Friday's close of $0.0398 equals $3.98 on an adjusted basis (calculated). Nasdaq set March 31, 2027 as the deadline to restore the minimum bid price. First-half revenue rose about 48% to $6.15 million, and cash was $295,256 at June 30, down from $2,387,158 at the end of 2025. The company also disclosed a plan for up to 383 million new shares in a September filing.
China SXT Pharmaceuticals: How Many Shares Remain After October 26?
A 1-for-100 consolidation takes effect Monday, October 26, leaving about 686,775 Class A shares. The adjusted equivalent of Friday's $0.0429 close is $4.29 (calculated). The company priced a $12 million offering at $1.50 on October 8, so the close is roughly 97.1% below that level (calculated). It has not announced a date for its next results.
Solowin Holdings: Does the Split Date Rest on Company Confirmation?
Market estimates list a 1-for-200 reverse split for October 26, though the date comes from a quote page rather than a company release. Friday's $0.0590 equals $11.80 on an adjusted basis (calculated). The company has not announced a catalyst for the 21.85% fall. Fiscal 2026 revenue rose about 895% to $28.05 million with a $13.29 million net loss. A September 21 prospectus supplement described a $2 million cash deal, and the stock is down about 97.5% over a year.
WiSeSat.Space: What Is Pending With No Date Attached?
A satellite launch with FOSSA Systems was confirmed on October 9 for October 2026, and reports differ on whether it has flown. The stock began trading October 2 and closed at $5.28 on October 22 before Friday's jump. Market estimates put its capitalization near $73 million at $6.91 (calculated). The company has not announced dates for the launch result or its first periodic filing.
Next Week Stocks Compared: Which Events Sit Closest and Which Bars Are Highest?
Counting from Friday, October 23, the three consolidations on October 26 are three days out (calculated). Tango Therapeutics' ESMO window closes four days out, MicroVision reports in five and LKQ and Phathom Pharmaceuticals in six (calculated). Friday's moves ranged from a 30.83% rise at WiSeSat.Space to a 21.85% fall at Solowin Holdings, a spread of 52.68 percentage points (calculated).
The balance sheets facing those events differ sharply. Tango Therapeutics' $1.0 billion of June 30 cash is about 5.5 times Phathom Pharmaceuticals' $182.5 million (calculated), and Phathom Pharmaceuticals' cash is about 6.7 times MicroVision's $27.2 million (calculated). The three pending consolidation names each closed below six cents, while MicroVision's $7.6 million to $12.6 million second-half revenue requirement is the clearest numeric hurdle among the reporters.
What to Watch Next: Which Days Matter Most Between October 26 and October 29?
Monday, October 26, 2026 brings the Top Wealth Group, China SXT Pharmaceuticals and Solowin Holdings consolidations. Tango Therapeutics' ESMO presentations conclude on October 27, MicroVision reports on October 28, and LKQ and Phathom Pharmaceuticals report on October 29. LKQ's new chief executive starts December 15, 2026. WiSeSat.Space and Tango Therapeutics have not announced dates for their respective launch result and third-quarter report.
MicroVision reports on October 28, and LKQ and Phathom Pharmaceuticals report on October 29.
Top Wealth Group and China SXT Pharmaceuticals are scheduled at 1-for-100, and market estimates list Solowin Holdings at 1-for-200.
No date has been announced. A satellite launch was confirmed for October 2026, but the company has not given a specific day.






Please wait processing your request...